Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (SB4) for the Treatment of Approved Etanercept Indications in the Republic of Ireland
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.741
https://www.valueinhealthjournal.com/article/S1098-3015(17)31075-6/fulltext
Section Title :
Disease-Specific Studies
Section Order :
706
First Page :
A529
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31075-6&doi=10.1016/j.jval.2017.08.741